Atossa Therapeutics Enters Material Definitive Agreement
Ticker: ATOS · Form: 8-K · Filed: Nov 19, 2024 · CIK: 1488039
| Field | Detail |
|---|---|
| Company | Atossa Therapeutics, INC. (ATOS) |
| Form Type | 8-K |
| Filed Date | Nov 19, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.18, $100,000,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement
Related Tickers: ATOS
TL;DR
ATOS signed a big deal, details TBD.
AI Summary
On November 19, 2024, Atossa Therapeutics, Inc. entered into a material definitive agreement. The filing does not provide specific details about the agreement, such as the counterparty or the financial terms involved.
Why It Matters
This filing indicates a significant new development for Atossa Therapeutics, potentially impacting its business operations and future strategies.
Risk Assessment
Risk Level: medium — The lack of specific details in the filing creates uncertainty about the nature and implications of the agreement.
Key Players & Entities
- Atossa Therapeutics, Inc. (company) — Registrant
- November 19, 2024 (date) — Date of Report
FAQ
What is the nature of the material definitive agreement entered into by Atossa Therapeutics?
The filing does not specify the nature of the agreement, only that a material definitive agreement was entered into on November 19, 2024.
Who is the counterparty to this material definitive agreement?
The filing does not disclose the identity of the other party involved in the agreement.
Are there any financial terms or obligations associated with this agreement?
The filing does not provide any details regarding the financial terms or obligations of the agreement.
When was the material definitive agreement entered into?
The agreement was entered into on November 19, 2024.
What is the purpose of this Form 8-K filing?
This Form 8-K is filed to report the entry into a material definitive agreement by Atossa Therapeutics, Inc.
Filing Stats: 1,049 words · 4 min read · ~3 pages · Grade level 13.7 · Accepted 2024-11-19 16:35:07
Key Financial Figures
- $0.18 — ge on which registered Common Stock , $0.18 par value ATOS The Nasdaq Capital M
- $100,000,000 — offer and sell from time to time up to $100,000,000 of shares of the Company's common stock
Filing Documents
- atos-20241119.htm (8-K) — 55KB
- atos-ex1_1.htm (EX-1.1) — 345KB
- atos-ex5_1.htm (EX-5.1) — 11KB
- img187741201_0.jpg (GRAPHIC) — 11KB
- img187741201_1.jpg (GRAPHIC) — 67KB
- 0000950170-24-128686.txt ( ) — 699KB
- atos-20241119.xsd (EX-101.SCH) — 28KB
- atos-20241119_htm.xml (XML) — 5KB
01 Entry Into a Material Definitive Agreement
Item 1.01 Entry Into a Material Definitive Agreement. On November 19, 2024, Atossa Therapeutics, Inc. (the "Company") entered into the Open Market Sale Agreement SM , dated November 19, 2024 (the "Sale Agreement"), with Jefferies LLC (the "Sales Agent"), pursuant to which the Company may offer and sell from time to time up to $100,000,000 of shares of the Company's common stock, par value $0.18 per share (the "Shares"), through the Sales Agent. The offering and sale of the Shares has been registered under the Securities Act of 1933, as amended (the "Securities Act"), pursuant to the Company's Registration Statement on Form S-3 (File No. 333-279367) (the "Registration Statement"), which was originally filed with the Securities and Exchange Commission ("SEC") on May 13, 2024 and declared effective by the SEC on May 23, 2024, the base prospectus contained within the Registration Statement, and a prospectus supplement that was filed with the SEC on November 19, 2024. Sales of the Shares, if any, pursuant to the Sale Agreement, may be made in sales deemed to be an "at the market offering" as defined in Rule 415(a)(4) promulgated under the Securities Act, including sales made directly on or through The Nasdaq Capital Market or on any other existing trading market for the Company's common stock. The Company has no obligation to sell any of the Shares under the Sale Agreement, and may at any time suspend offers under the Sale Agreement or terminate the Sale Agreement. The Sales Agent will act as a sales agent and will use commercially reasonable efforts to sell on the Company's behalf all of the Shares requested to be sold by the Company, consistent with their normal trading and sales practices, on mutually agreed terms between the Sales Agent and the Company. The Company currently intends to use the proceeds of the offering, if any, for clinical development of its product candidates, working capital and general corporate purposes. The Company may also use a portion of
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits 1.1 Open Market Sale Agreement SM , dated November 19, 2024, by and between Atossa Therapeutics, Inc. and Jefferies LLC 5.1 Opinion of Gibson, Dunn & Crutcher LLP 23.1 Consent of Gibson, Dunn & Crutcher LLP (contained in Exhibit 5.1) 104 Cover page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Atossa Therapeutics, Inc . Date: November 19, 2024 By: /s/ Heather Rees Heather Rees Chief Financial Officer